FDA Accepts Axsome's AXS-12 NDA for Narcolepsy Cataplexy, Setting May 2027 PDUFA Date

summarizeSummary

The FDA has accepted the NDA for AXS-12 in narcolepsy cataplexy, with a PDUFA date of May 1, 2027. No advisory committee is currently planned, signaling a potentially smooth review.

check_boxKey Events · Product Development and Regulatory · AXSM

• FDA Accepts AXS-12 NDA

  The FDA has accepted the New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, a serious orphan neurological condition.

• PDUFA Date Set for May 1, 2027

  A clear regulatory timeline is now in place, with the FDA setting a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.

• No Advisory Committee Planned

  The FDA indicated it does not currently plan to hold an advisory committee meeting, suggesting a straightforward review process and reducing a common source of uncertainty.

• Pipeline Expansion in CNS

  AXS-12 strengthens a growing CNS portfolio that already includes approved treatments for major depressive disorder, Alzheimer's agitation, excessive daytime sleepiness, and migraine.

auto_awesomeAnalysis · AXSM · Life Sciences

A major pipeline milestone has been reached with the FDA's acceptance of the NDA for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, setting a PDUFA date of May 1, 2027. For a company with a $12.1B market cap, this adds a promising new indication to its CNS portfolio. The review path looks smoother than usual because the FDA currently does not plan an advisory committee meeting, removing a common overhang. Combined with recent strong commercial execution and a settled patent landscape for Sunosi, this regulatory catalyst reinforces the growth narrative.